A real rally does not ride on five stocks. It spreads.

Yesterday, the market ripped higher, and this time it was not just the usual tech giants doing the heavy lifting.

The small and mid-sized names led the way, with the Russell 2000 jumping over 3%, beating the big indexes.

That matters more than the green numbers themselves.

When the little guys lead, it tells you money is finally fanning out across the market instead of hiding in a handful of mega-caps.

That is what a healthy rally looks like, and it is the kind of move that tends to keep going.

So the question I am asking is simple. If money is broadening out, where does it go next?

One group near the top of my list is biotech, and the cleanest way I watch the whole space at once is the XBI.

Here is why the XBI is the right tool.

It is an equal-weight basket of around 150 biotech names, and no single stock makes up much more than 1.5% of it.

And this is not a basket of lottery tickets. Look at the kind of names inside it. Revolution Medicines is going after RAS-mutated cancers, the pancreatic and lung tumors that doctors have called undruggable for forty years, and it has a real pipeline taking a swing at them.

Apellis already sells two approved drugs and owns most of the market in a serious eye disease. Alkermes just bought its way into a bigger sleep-medicine business and has a narcolepsy drug the FDA already fast-tracked. These are companies with real products and real catalysts, not science projects.

The XBI lets me own the whole field of them at once, so when the group catches a bid, I am riding the strongest names without having to pick which trial reads out right.

And the backdrop for the whole industry is shifting fast.

For decades, discovering a drug meant ten years and a couple billion dollars, with most attempts failing.

Now AI is starting to chip away at that.

The research says it can cut the time and cost of early drug discovery by a quarter to a half, and the FDA opened a faster lane this year for drugs developed with it.

That does not turn every biotech into a tech company overnight, but it lowers the cost of the whole game, and money has noticed. Biotech buyout deals have already crossed $100 billion this year.

When a slow, expensive industry starts getting faster and cheaper, the whole sector gets more attractive, and a basket like the XBI is how you ride that without betting on a single name.

Now to the chart, because this is where I get interested the most as a trader.

Start with the big picture. On the weekly, the moving averages are stacked in the right order, the faster ones above the slower ones, all pointed up. That tells me the long-term trend is healthy and the buyers have been in control for months.

Zoom into the daily and you see something different, and I like it.

The XBI has stopped running and started coiling, trading in a tighter and tighter range since the spring. That is a squeeze. Think of a spring being slowly compressed, storing energy with nowhere to go yet. The longer it winds, the harder it tends to pop when it finally lets loose.

So I have a long-term trend pointing up and a daily that is winding into a tight coil right underneath it. That is a strong trend taking a breather and loading up, not a top.

Your Action Plan

While all eyes will be on the biggest IPO in history today, I’m watching for this market to broaden out from just a few semiconductor and AI stocks.

Which I think is necessary if we expect the rally to continue. I’ll be watching SpaceX from the sidelines today. Wait for the options to start trading before I decide anything there.

But right now, I’m looking at names like XBI.

If you want to know the rest, it’s simple.

Come trade it with me in Daily Profits Live.